Jerald Korn - 12 Aug 2022 Form 4 Insider Report for Epizyme, Inc.

Role: Chief Operating Officer
Signature: /s/ John Weidenbruch, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 12 Aug 2022
Net transactions value: $0
Form type: 4
Filing time: 16 Aug 2022, 18:55:41 UTC
Previous filing: 04 Apr 2022
SEC: View on sec.gov

Jerald Korn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Remarks:

This "Exit" Form 4 is voluntarily filed to report that in connection with that certain Agreement and Plan of Merger, by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc., dated as of June 27, 2022, the Reporting Person is no longer subject to Section 16 reporting.